

# Biostatistics

## Applications in Serological Data Analysis

Nuno Sepúlveda, 19.01.2026

# Syllabus

## 1. General review

- a. Population/Sample/Sample size
- b. Type of Data – quantitative and qualitative variables
- c. Common probability distributions/popular tests

## 2. Applications in Medicine

- a. Construction and analysis of diagnostic tools – Binomial distribution, ROC curve, sensitivity, specificity, Rogal-Gladen estimator
- b. Estimation of treatment effects - generalized linear models
- c. Survival analysis - Kaplan-Meier curve, log-rank test, Cox's proportional hazards model

## 3. Applications in Genetic and Epigenetic Data

- a. Genetic association studies – Hardy-Weinberg test, homozygosity, minor allele frequencies, additive model, multiple testing correction
- b. Methylation association studies – M versus beta values

## 4. Applications in Serological Data Analysis

- a. Determination of seropositivity using Gaussian mixture models
- b. Reversible catalytic models for estimating seroconversion rate
- c. Sample size calculation for estimating seroconversion rate

# Exercise: data\_serology.csv

## Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study

Jason Rosado, Stéphane Pelleau, Charlotte Cockram, Sarah Hélène Merkling, Narimane Nekkab, Caroline Demeret, Annalisa Meola, Solen Kerneis, Benjamin Terrier, Samira Fafi-Kremer, Jerome de Seze, Timothée Bruel, François Dejardin, Stéphane Petres, Rhea Longley, Arnaud Fontanet, Marija Backovic, Ivo Mueller, Michael T White




Focus on data from participants with status = positive (samples collected during the pandemic)

Estimate a two-Gaussian mixture model for S1RBD\_NA\_IgG\_dil or S1RBD\_NA\_IgG\_MFI using package mixtools.  
Estimate the 3-sigma cutoff and the respective sensitivity and specificity. Estimate the raw seroprevalence and corrected seroprevalence using the Rogan-Gladen Estimator.

Do you think the two-Gaussian mixture model is adequate for the data?



## 2. Estimating seroconversion rate (using reversible catalytic models)

# Reversible catalytic models



How can you model this stochastic process?


# Constant transmission intensity



# Markov chain formulation

$$P_t = P_0 e^{Qt} \quad P_0 = \begin{pmatrix} 1 \\ 0 \end{pmatrix} \quad Q = \begin{pmatrix} -\lambda & \lambda \\ \rho & -\rho \end{pmatrix}$$
$$e^{Qt} = \begin{pmatrix} \frac{\rho}{\lambda + \rho} + \frac{\lambda}{\lambda + \rho} e^{-(\lambda + \rho)t} & \frac{\lambda}{\lambda + \rho} (1 - e^{-(\lambda + \rho)t}) \\ \frac{\rho}{\lambda + \rho} (1 - e^{-(\lambda + \rho)t}) & \frac{\lambda}{\lambda + \rho} + \frac{\rho}{\lambda + \rho} e^{-(\lambda + \rho)t} \end{pmatrix}$$


# Longitudinal surveys



**Statistical information:** ++++  
Direct observation of serological transitions

**Execution difficulty:** ++++  
Time consuming  
Sampling intensive  
Participation adherence/drop-outs

# Cross-sectional surveys



**Statistical information:** ++

No direct observation of serological transitions  
Age as proxy of time

**Execution difficulty:** ++

Easy to engage participation  
Quick sampling

What is the sampling model?

# Longitudinal versus cross-sectional surveys

Type of Study	Seroconversion rate	Seroreversion rate
Longitudinal	<b>0.021</b> (0.001-0.096)	<b>0.163</b> (0.001,0.729)
Cross-sectional	<b>0.023</b> (0.001,0.052)	<b>0.0001</b> (0.001,0.255)

Why is the seroreversion rate estimated differently using these two types of surveys?



## Fixed seroreversion rate at 0

$$\rho = 0 \Rightarrow \pi_t = 1 - e^{-\lambda t}$$

$$\Rightarrow \log(1 - \pi_t) = -\lambda t \qquad \text{Do you know this model?}$$

$$\Rightarrow \log(-\log(1 - \pi_t)) = \log \lambda + \log t \qquad \text{Do you know this model?}$$

What are the practical implications in terms of model fitting?

# Exercise: data\_bioko.csv

OPEN  ACCESS Freely available online




## Serological Markers Suggest Heterogeneity of Effectiveness of Malaria Control Interventions on Bioko Island, Equatorial Guinea

**Jackie Cook<sup>1</sup>, Immo Kleinschmidt<sup>2</sup>, Christopher Schwabe<sup>3</sup>, Gloria Nseng<sup>4</sup>, Teun Bousema<sup>1</sup>, Patrick H. Corran<sup>1</sup>, Eleanor M. Riley<sup>1</sup>, Chris J. Drakeley<sup>1\*</sup>**

**1** Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom, **2** Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom, **3** Medicinal Care Development International, Silver Spring, Maryland, United States of America, **4** Ministry of Health and Social Welfare, Malabo, Equatorial Guinea

# Exercise: data\_bioko.csv



# Exercise: data\_bioko.csv

**Table 1.** Demographic characteristics of the study population.

% [n]							
		Malabo N = 2328	North West N = 1749	North East N = 1323	South East N = 700	South West N = 588	Other** N = 699
<b>Age (years)</b>	0–1	14.1 [324]	10.5 [182]	10.4 [137]	12.2 [85]	10.0 [58]	7.5 [52]
	1–5	21.1 [458]	18.0 [312]	19.8 [261]	14.6 [102]	16.8 [97]	15.2 [106]
	5–15	26.3 [605]	30.6 [531]	30.1 [396]	21.0 [146]	24.0 [139]	28.7 [200]
	15–90	38.6 [890]	41.0 [712]	39.8 [524]	52.2 [364]	49.2 [285]	48.6 [338]
<b>Sex</b>	Female	61.2 [1410]	54.2 [932]	61.1 [805]	55.8 [389]	58.4 [338]	54.8 [382]
<b>House recently sprayed<sup>1</sup></b>	Yes	74.2 [1580]	81.2 [1306]	85.6 [1076]	81.7 [519]	89.5 [477]	87.9 [574]
<b>Slept under ITN<sup>2</sup></b>	Yes	82.6 [1629]	68.0 [988]	65.8 [797]	63.3 [404]	73.1 [385]	71.4 [449]
<b>Parasite positive</b>	Yes	14.8 [300]	27.0 [374]	7.9 [94]	21.7 [135]	18.6 [97]	12.1 [75]
<b>Total N = 7387</b>							

<sup>1</sup>- within the previous 6 months.

<sup>2</sup>- on the night before the survey.

\*\*Moca and Musola kept separate due to their high altitude.

doi:10.1371/journal.pone.0025137.t001

## Exercise: data\_bioko.csv



Estimate a two-Gaussian mixture model to serological data related to antibody against PfAMA1 protein (Ab\_pfama1\_titers) using mixtools package (normalmixEM command). Calculate the  $3\sigma$ -rule cutoff and apply it to determine the serological status of each individual (seronegative/seropositive).

Estimate a reversible catalytic model in the seropositive data from the North West district with a seroreversion rate=0 using glm function and offset of the covariate log(Age). What is the estimate of the seroconversion rate? Does this model fit the data well?

Estimate a reversible catalytic model with constant seroconversion and seroreversion rates using seroaid source. Compare the seroconversion rate estimate with the previous one.


### 3. Calculating sample size for controlling precision of seroconversion rate estimate

# Sample size calculation for seroconversion rate



# Wald's confidence interval

# Sample size calculation for seroconversion rate



# Sample size calculation in practice


1. Desired precision
2. Antibody with known seroreversion rate
3. Transmission intensity of the population
4. Age structure associated with sampling scheme
5. Type of confidence interval to be used

# Identification of transmission intensity


**Table 1 Expected relationship between EIR, PR<sub>04</sub>, SCR and SP in African (AFR), Southeast Asian and South American (SEA + SA) populations where seroreversion rate was fixed at 0.017**

EIR	PR <sub>04</sub>	SCR	Seroprevalence	
			AFR	SEA + SA
0.01	0.050	0.0036	0.057	0.073
0.10	0.073	0.0108	0.156	0.195
1.00	0.119	0.0324	0.365	0.437
10.0	0.231	0.0969	0.647	0.720
100.0	0.625	0.2900	0.860	0.896

# Identification of transmission intensity



# Identification of age structure



# Type of confidence interval

## Pearson-Clopper exact

Coverage higher than nominal confidence level

## Wald

Degenerate when  $x=0$  or  $x=n$

Overshooting


## Wilson

Good coverage in extreme probabilities

## Agresti-Coull

Overshooting

Better coverage than the exact CI



# Exercise:

Estimate the sample size for estimating the estimated seroconversion rate in the previous exercise assuming the age distribution of north West region and a fixed seroreversion rate of 0.017.

Aim to estimate the seroconversion with a relative length of 0.1, 0.25, and 0.5 of 95% confidence interval.

Use package RCMsize and command sample\_s.